Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise

Clinical Lymphoma, Myeloma & Leukemia
Ogunleye FolusoIshmael Jaiyesimi

Abstract

The recent discovery of the role of the B-cell antigen receptor (BCR) signaling pathway in the propagation and maintenance of both normal B-cell function and in B-cell malignancies has highlighted the importance of many protein kinases involved in BCR signal propagation. Considerable research attention has focused on the Bruton tyrosine kinase (BTK) as a potential therapeutic target in B-cell malignancies. Treatment paradigms including ibrutinib, a potent inhibitor of the BTK recently approved by the US Food and Drug Administration, have significantly improved disease outcome among high-risk and relapsed/refractory cases of chronic lymphocytic leukemia. This has provided additional treatment options, especially among the elderly, where improved disease response has been accompanied by more manageable treatment-associated toxicity than commonly found with chemoimmunotherapy. In this review, we provide a synopsis of the current data on the efficacy and clinical utilization of ibrutinib and management of its resistance in the treatment of chronic lymphocytic leukemia.

References

Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·S J SaouafJ B Bolen
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y AokiS Pillai
Oct 6, 2000·The Journal of Cell Biology·C M BrennanJ A Steitz
Jan 12, 2002·Developmental Immunology·A Maas, R W Hendriks
Jun 29, 2004·Molecular Immunology·Joseph M Dal PortoJohn Cambier
Mar 25, 2006·Nature Reviews. Immunology·John G Monroe
Jan 17, 2009·Cancer Research·Sarah C MutkaSumati Murli
Mar 9, 2010·Cellular Signalling·J Michael Bradshaw
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Jun 4, 2011·Expert Opinion on Therapeutic Targets·Rudi W HendriksFrank Jt Staal
Aug 6, 2011·Blood·Freda K StevensonGraham Packham
Mar 28, 2012·International Reviews of Immunology·Bruno CenniMarie Gottar-Guillier
Jul 27, 2012·Molecular Biology of the Cell·Darui XuYuh Min Chook
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adrian Wiestner
Jan 9, 2013·Current Hematologic Malignancy Reports·Jennifer R Brown
Apr 27, 2013·International Reviews of Immunology·Tadeusz Robak, Pawel Robak
Oct 12, 2013·British Journal of Haematology·Amin Aalipour, Ranjana H Advani
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Aug 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur

❮ Previous
Next ❯

Citations

Jul 18, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Krystal S Titus-RainsJulia M Hammond

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ranjana H AdvaniNathan H Fowler
Clinical Pharmacology and Therapeutics
L AlinariKristie A Blum
Hematology/oncology Clinics of North America
Nitin Jain, Susan O'Brien
© 2022 Meta ULC. All rights reserved